Opendata, web and dolomites

pBioStrat-for-PDA SIGNED

Use of PAP as a biomarker and stratifier of pancreatic cancer to improve patient management

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 pBioStrat-for-PDA project word cloud

Explore the words cloud of the pBioStrat-for-PDA project. It provides you a very rough idea of what is the project "pBioStrat-for-PDA" about.

characterizing    ductal    jak2    interestingly    patients    clinical    tumor    chemotherapy    pda    2011    physiology    candidates    criteria    biological    solid    took    serum    2016    stat3    acinar    clinicians    figures    microenvironment    peri    resectability    surgery    last    invasion    revealed    mortality    negative    understand       predict    compartment    grant    biomarker    titration    unnecessary    consequence    80    erc    secreted    stromal    tumoral    tumors    90    cells    stratify    pbiostrat    outlook    potent    optimization    constitutes    starting    shortening    limiting    fundamental    reg3a    cellular    improvements    context    start    worst    neglecting    neural    signalling    palliative    trials    cohorts    trying    rate    survival    conceptual    redirection    opened    specificity    consists    incidence    invasive    managements    powerful    with    delay    pancreatic    validation    prognosis    pap    tool    panr    poc    demonstrated    discoveries    nature    adenocarcinoma    progresses    morbidity    cancer   

Project "pBioStrat-for-PDA" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 150˙000.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

With an overall 3-year survival rate of only ~6% together with an increased incidence pancreatic ductal adenocarcinoma (PDA), which represents 90% of pancreatic cancer, figures as the solid cancer with the worst prognosis. In trying to understand “the” reason for such negative outlook, one has to consider that the fundamental and clinical research conducted during the last 30 years has focused on characterizing and understanding the properties of the PDA cancer cells, neglecting the specific cellular context of those tumors. Indeed PDA consists of 80% of non-tumor cells. In the ERC Starting grant, S-Target-in-PANR, I conducted from 2011 to 2016 we took into account this specificity and analyzed the impact of this stromal compartment on PDA physiology. The discoveries and conceptual progresses obtained throughout the S-Target-in-PANR programme opened new potent improvements of PDA patients’ management. Among them, we revealed that one of the candidates, PAP/REG3A, was secreted by acinar cells from the peri-tumoral microenvironment to enhance peri-neural invasion ability of tumor cells. Interestingly, we demonstrated that PAP/REG3A titration in serum was a potent biomarker in order to stratify PDA and could lead to patients’ management optimization and more specifically to predict resectability. This validation, using robust cohorts and adapted testing, constitutes the main goal of our ERC-PoC pBioStrat-for-PDA. Indeed, it will provide a powerful tool for clinicians in order to better determine the resectability of a tumor by taking into account its biological nature on top of the only clinical criteria used so far. As a consequence the use of a non-invasive PAP/REG3A serum level determination will improve patients’ managements by (1) shortening the delay to start palliative chemotherapy, (2) limiting unnecessary surgery with important mortality/morbidity and (3) improving their redirection to adapted clinical trials, as the one targeting JAK2/STAT3 signalling.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PBIOSTRAT-FOR-PDA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PBIOSTRAT-FOR-PDA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

HyperCube (2020)

HyperCube: Gram scale production of ferrite nanocubes and thermo-responsive polymer coated nanocubes for medical applications and further exploitation in other hyperthermia fields

Read More  

inSight (2019)

Moving a novel gene therapy paradigm to treat blindness to the market

Read More  

MCS-MD (2019)

The Molecular Dynamics of Membrane Contact Sites

Read More